Cowen Starts Acrivon Therapeutics Inc (ACRV) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ACRV Hot Sheet
Price: $1.73 -1.7%
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
10 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Cowen analyst Joseph Thome initiates coverage on Acrivon Therapeutics Inc (NASDAQ: ACRV) with a Outperform rating.
For an analyst ratings summary and ratings history on Acrivon Therapeutics Inc click here. For more ratings news on Acrivon Therapeutics Inc click here.
Shares of Acrivon Therapeutics Inc closed at $12.50 yesterday.
You May Also Be Interested In
- Acrivon targets AML with oral CDK11 inhibitor, IND set for 2027
- Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
- Cantor Fitzgerald Starts Quantum Corp. (QMCO) at Overweight
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
